OptiNose AS Announces First Patient Enrolled in Phase III Study of Sumatriptan Powder Delivered Intranasally with Innovative Bi-directional Device
2/9/2012 7:48:40 AM
More...
|
OptiNose AS Files Investigational New Drug Application to use Sumatriptan Delivered with its Novel Drug Delivery Technology
2/3/2012 6:15:20 AM
More...
|
OptiNose AS Selects BioClinica, Inc.'s Trident IWR, Optimizer and Imaging Core Lab Solutions
9/8/2011 10:00:56 AM
More...
|
OptiNose AS Standardizes on Medidata Solutions, Inc. Rave Clinical Technology
8/30/2011 10:44:43 AM
More...
|
OptiNose AS Bi-Directional Drug Delivery Technology Wins Innovation Award for Potential Benefits of Nose to Brain Application
5/23/2011 11:07:18 AM
More...
|
OptiNose AS Receives Nearly $489,000 Grant Award under U.S. Government Qualifying Therapeutic Discovery Project Program
11/3/2010 11:43:30 AM
More...
|
Rapid Absorption Rate Alone May Not Explain Efficacy in Migraines of Sumatriptan Delivered with OptiNose AS's Novel Drug Delivery Technology
10/28/2010 12:10:09 PM
More...
|
OptiNose AS Announces Publication of Positive Subgroup Analysis Evaluating Efficacy of Fluticasone Delivered with Novel Drug Delivery Technology
8/10/2010 9:21:59 AM
More...
|
Avista Capital Partners Commits $48.5 Million to OptiNose AS to Develop an Innovative Nasal Drug Delivery Technology Slated to Begin Phase III Trials
6/8/2010 7:00:58 AM
More...
|